Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The goal of this clinical research study is to find the highest safe dose of olaparib that can be combined with chemotherapy drugs and stem cell transplantation to treat patients with relapsed and refractory germ cell cancer. The safety and effectiveness of this treatment combination therapies will also be studied.
Full description
Primary Objectives:
Secondary Objectives:
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
12 - 60 years of age.
Diagnosis of relapsed GCT, with one or more of the following criteria:
ECOG PS ≤ 2 (Karnofsky ≥ 60%).in adults, Lansky Play-Performance Scale (LPPS) ≥ 60% in pediatric patients.
A minimum apheresis collection of 5 million CD34+ cells/kg of autologous peripheral blood progenitor cells (PBPC).
Adequate blood counts (WBC ≥ 2K, HGB ≥ 8 g/dL, platelets ≥ 50K).
Creatinine clearance ≥ 50 ml/min/1.73 m2 (estimated by the Cockroft-Gault method in adults and the Schwartz formula in pediatric patients) and/or serum creatinine ≤ 1.8 mg/dL.
ALT and/or AST ≤ 3 x institutional ULN, and bilirubin and alkaline phosphatase (ALP) ≤ 2 x institutional ULN.
FE 1, F and DL Oc ≥ 0%
L EF ≥ 0%, without active arrythmias
If female of child-bearing potential, she must not be pregnant or breastfeeding and required to have a negative urine or serum pregnancy test prior to enrollment.
For patients at risk for hepatitis B (HBV) reactivation (HBsAg+/negative HBV viremia, or HBsAg-/anti-HBc+) will be eligible as long as they are on suppressive antiviral therapy.
Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection still on treatment, they are eligible if they have an undetectable HCV viral load.
Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression.
Patients with a prior or concurrent malignancy whose natural history or treatment does not interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or lower.
Male patients and women of child-bearing potential whose partners are participating in the study must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. (Refer to Pregnancy Assessment Policy MD Anderson Institutional Policy # CLN1114).
Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to treatment initiation (specify timeframe) and for the duration of study treatment (and if necessary, specify how long after treatment is completed) . (Refer to Pregnancy Assessment Policy UT MD Anderson Institutional Policy # CLN1114). This includes all female patients, between the onset of menses (as early as 8 years of age) and 55 years unless the patient presents with an applicable exclusionary factor which may be one of the following:
Postmenopausal (no menses in greater than or equal to 12 consecutive months).
History of hysterectomy or bilateral salpingo-oophorectomy.
Ovarian failure (Follicle Stimulating Hormone and Estradiol in menopausal range, who have received whole pelvic radiation therapy).
History of bilateral tubal ligation or another surgical sterilization procedure.
Ability to understand and willingness to sign a written informed document by patients and/ or their parents or legal guardians. Minors ages 7 and older must give their assent to participate
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
36 participants in 1 patient group
Loading...
Central trial contact
Yago Nieto, MD, PHD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal